Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript

Page 4 of 4

So it’s hard to make a qualified guess on the protein dose at this point.

Operator: At this point, it seems there are no further questions. I would now turn the conference over to Thomas Gad for closing remarks.

Thomas Gad : All right. Thank you. And thank you, everyone, for joining us today. Q4 has undoubtedly been a busy quarter for all of us. DANYELZA revenues were higher than ever, and international operations are going very well. So we believe Y-mAbs remains well-positioned financially as well as operationally. So thank you for spending time with us today. Have a great day. Bye, bye.

Operator: Ladies and gentlemen, this does conclude today’s teleconference. You may disconnect your lines at this time. Thank you for your participation, and have a wonderful day.

Follow Y-Mabs Therapeutics Inc.

Page 4 of 4